2 citations
,
February 2014 in “Journal of Crohn's and colitis” Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
August 1998 in “Parasitology International” 18 citations
,
February 2023 in “eLife” ILC1-like cells can independently cause alopecia areata.
19 citations
,
December 2011 in “PubMed” Inflammation and immunity play a key role in androgenetic alopecia, with better treatment outcomes in certain immune-positive cases.
2 citations
,
June 2025 in “Journal of Investigative Dermatology” CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.
107 citations
,
July 1991 in “Journal of Allergy and Clinical Immunology”
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
1 citations
,
June 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Fetal skin has unique immune cells different from adult skin.
5 citations
,
May 2015 in “The Journal of Dermatology” Topical corticosteroids can help treat severe alopecia areata when other treatments fail.
17 citations
,
January 2015 in “Dermatology online journal” A patient's grey hair regained color during treatment with adalimumab.
58 citations
,
July 2018 in “Journal of Allergy and Clinical Immunology” Alopecia areata severity is linked to increased TH1 and TH2 activity.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Higher monocyte counts may predict poor response to adalimumab in hidradenitis suppurativa patients.
9 citations
,
January 2015 in “Dermatology Online Journal” A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.
July 2024 in “Clinical Cosmetic and Investigational Dermatology” Certain immune cells are linked to non-scarring hair loss, suggesting potential for immune-targeted treatments.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.
September 2023 in “Journal of the American Academy of Dermatology” ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.
November 2025 in “Skin Appendage Disorders” Immune cell-targeting biologics show potential for treating alopecia areata but need better-targeted therapies.
July 2025 in “Journal of Investigative Dermatology” Monocyte-derived dendritic cells play a key role in UVB-induced skin sensitivity and inflammation.
November 2025 in “Indian Journal of Nephrology” Hair dye may trigger anti-GBM disease relapse, and rituximab can help manage it.
48 citations
,
January 2024 in “Immune Network” IL-15 is key for T cell function and could help improve treatments for immune-related diseases.
June 2025 in “Medical Science Journal for Advance Research” Higher levels of MIG and IP-10 may help diagnose and monitor Alopecia Areata.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.
February 2025 in “Infectious Diseases & Immunity” HHV-6 reactivation may be linked to psychiatric disorders and can improve with antiviral treatment.
January 2026 in “Immunological Reviews” Females generally have stronger immune responses than males due to the X chromosome.
107 citations
,
December 2003 in “Dermatologic Therapy” Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.
9 citations
,
April 2016 in “Australasian journal of dermatology” Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.
June 2026 in “Frontiers in Oncology” Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.
1 citations
,
May 2025 in “Clinical Reviews in Allergy & Immunology” 12 citations
,
April 2017 in “Experimental and Therapeutic Medicine” Patients with severe active alopecia areata have lower CD200 expression and an imbalance in their immune system.
January 2026 in “Case Reports in Rheumatology” Rituximab improved her dermatomyositis better than usual treatments.